Adaptin Bio (APTN) EBIT (2023 - 2026)

Adaptin Bio has disclosed EBIT across 4 years of filings, most recently posting -$1.1 million for Q1 2026.

• Quarterly EBIT fell 34.53% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (down 14.29% YoY) and the FY2025 annual result came in at -$1.1 million, down 65.49% from the prior year.
• EBIT slipped to -$1.1 million in Q1 2026, from $3.0 million in the prior quarter.
• Across five years, EBIT topped out at $3.0 million in Q4 2025 and bottomed at -$1.7 million in Q3 2025.
• The 4-year median for EBIT is -$767320.0 (2024), against an average of -$269288.5.
• The widest YoY moves for EBIT: up 4216.73% in 2024, down 2216.71% in 2024.
• Adaptin Bio's EBIT stood at -$34155.0 in 2023, then jumped by 4216.73% to $1.4 million in 2024, then soared by 110.64% to $3.0 million in 2025, then sank by 138.63% to -$1.1 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$1.1 million, $3.0 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.